Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 35,770 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 35,770 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $0.32, for a total transaction of $11,446.40. Following the sale, the director directly owned 107,429 shares of the company’s stock, valued at $34,377.28. This represents a 24.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, July 7th, Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total transaction of $12,741.08.

Werewolf Therapeutics Price Performance

HOWL stock traded up $0.02 during midday trading on Wednesday, reaching $0.36. 590,804 shares of the stock were exchanged, compared to its average volume of 539,946. Werewolf Therapeutics, Inc. has a 52 week low of $0.27 and a 52 week high of $2.38. The company has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.63. The stock has a market capitalization of $17.49 million, a PE ratio of -0.29 and a beta of 0.30.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics presently has an average rating of “Hold” and an average price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP increased its holdings in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Regal Investment Advisors LLC grew its position in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the period. Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at $48,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.